SG11202105437UA - Induction of sustained local inflammation - Google Patents

Induction of sustained local inflammation

Info

Publication number
SG11202105437UA
SG11202105437UA SG11202105437UA SG11202105437UA SG11202105437UA SG 11202105437U A SG11202105437U A SG 11202105437UA SG 11202105437U A SG11202105437U A SG 11202105437UA SG 11202105437U A SG11202105437U A SG 11202105437UA SG 11202105437U A SG11202105437U A SG 11202105437UA
Authority
SG
Singapore
Prior art keywords
induction
local inflammation
sustained local
sustained
inflammation
Prior art date
Application number
SG11202105437UA
Inventor
David B Rosen
Luis Zuniga
Juha Punnonen
Lars Holten-Andersen
Kennett Sprogøe
Yang Yang-Malten
Torben Lessmann
Nicola Bisek
Samuel Weisbrod
Sebastian Stark
Tobias Voigt
Original Assignee
Ascendis Pharma Oncology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Oncology Div A/S filed Critical Ascendis Pharma Oncology Div A/S
Publication of SG11202105437UA publication Critical patent/SG11202105437UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG11202105437UA 2019-01-04 2020-01-03 Induction of sustained local inflammation SG11202105437UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19150385 2019-01-04
EP19181820 2019-06-21
EP19206487 2019-10-31
PCT/EP2020/050096 WO2020141223A1 (en) 2019-01-04 2020-01-03 Induction of sustained local inflammation

Publications (1)

Publication Number Publication Date
SG11202105437UA true SG11202105437UA (en) 2021-06-29

Family

ID=69147694

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105437UA SG11202105437UA (en) 2019-01-04 2020-01-03 Induction of sustained local inflammation

Country Status (7)

Country Link
US (1) US20220054477A1 (en)
EP (1) EP3906018A1 (en)
AU (1) AU2020204786A1 (en)
CA (1) CA3125488A1 (en)
IL (1) IL284439A (en)
SG (1) SG11202105437UA (en)
WO (1) WO2020141223A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023110727A2 (en) * 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
AU2004228793B2 (en) 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
JP2010533202A (en) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド Polymeric drug delivery system comprising a polysubstituted aromatic moiety
LT2237799T (en) 2008-02-01 2019-07-25 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
JP2011520983A (en) 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド Polymer systems containing intracellular releasable disulfide linkers for oligonucleotide delivery
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
WO2011139348A2 (en) * 2010-04-30 2011-11-10 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
ES2584381T3 (en) 2010-05-05 2016-09-27 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
WO2013024053A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
BR112014003225A2 (en) 2011-08-12 2017-03-01 Ascendis Pharma As vehicle-linked treprostinil prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
SG11201400815TA (en) 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
RU2647729C2 (en) 2012-10-11 2018-03-19 Асцендис Фарма Ас Hydrocarbon gel-based prodrugs
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
KR102608645B1 (en) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 Novel polymeric hgh prodrugs
US11179385B2 (en) * 2015-06-30 2021-11-23 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
AU2017321609C1 (en) * 2016-08-30 2023-11-09 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
WO2018067702A1 (en) * 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Bottlebrush copolymers and uses thereof
EP3568162A1 (en) * 2017-01-10 2019-11-20 Nektar Therapeutics Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
KR20200007776A (en) 2017-03-22 2020-01-22 제넨테크, 인크. Hydrogel Crosslinked Hyaluronic Acid Prodrug Compositions and Methods

Also Published As

Publication number Publication date
US20220054477A1 (en) 2022-02-24
CA3125488A1 (en) 2020-07-09
AU2020204786A1 (en) 2021-06-10
IL284439A (en) 2021-08-31
EP3906018A1 (en) 2021-11-10
WO2020141223A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
IL279468A (en) Crystal modifications of odevixibat
IL273693A (en) Treatment of inflammatory disorders
GB2587918B (en) Continuous isolation of cannabidiol
EP4069212A4 (en) Inhibitors of hif-2alpha
IL286218A (en) Solid state forms of ripretinib
EP4017503A4 (en) Ddx17 and nlrc4 targeting for inflammatory diseases
IL276592A (en) Derivatives of sobetirome
GB2575780B (en) Walkway installation
EP3894768C0 (en) Methods of cryo-curing
IL288761A (en) Inductor
IL284440A (en) Minimization of systemic inflammation
IL284439A (en) Induction of sustained local inflammation
GB201713475D0 (en) Frequency converter
GB201820471D0 (en) Nanoparticle-based therapy of inflammatory disorders
PL3572159T3 (en) Methods of forming ultra-conductive wires
IL285119A (en) Use of spiropidion
IL276107A (en) Solid forms of fasoracetam
SG11202105136WA (en) Application of chidamide
EP3897642A4 (en) Methods of treating inflammation
EP3774849A4 (en) Treatment of inflammation
EP3897325C0 (en) Installation of hygiene equipment
GB201902657D0 (en) He supercap
CA194176S (en) Field of view reducer
GB201703041D0 (en) Installation of mono-pile
GB201816914D0 (en) Treatment of inflammation